Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

121. Home-based rehabilitation for COPD using minimal resources: a randomised, controlled equivalence trial

Home-based rehabilitation for COPD using minimal resources: a randomised, controlled equivalence trial Pulmonary rehabilitation is a cornerstone of care for COPD but uptake of traditional centre-based programmes is poor. We assessed whether home-based pulmonary rehabilitation, delivered using minimal resources, had equivalent outcomes to centre-based pulmonary rehabilitation.A randomised controlled equivalence trial with 12 months follow-up. Participants with stable COPD were randomly assigned (...) group maintained postrehabilitation gains at 12 months.This home-based pulmonary rehabilitation model, delivered with minimal resources, produced short-term clinical outcomes that were equivalent to centre-based pulmonary rehabilitation. Neither model was effective in maintaining gains at 12 months. Home-based pulmonary rehabilitation could be considered for people with COPD who cannot access centre-based pulmonary rehabilitation.NCT01423227, clinicaltrials.gov.Published by the BMJ Publishing Group

Full Text available with Trip Pro

2016 EvidenceUpdates

122. Chronic obstructive pulmonary disease (COPD): smoking cessation and appropriate medication

Chronic obstructive pulmonary disease (COPD): smoking cessation and appropriate medication Prescrire IN ENGLISH - Spotlight ''Chronic obstructive pulmonary disease (COPD): smoking cessation and appropriate medication'', 1 November 2016 {1} {1} {1} | | > > > Chronic obstructive pulmonary disease (COPD): smoking cessation and appropriate medication Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Chronic obstructive pulmonary disease (COPD): smoking cessation and appropriate medication Drug treatments for COPD are effective chiefly against the symptoms and should be adjusted according to the progression of the disease. Chronic obstructive pulmonary disease or COPD is a chronic inflammation of the respiratory tract, with the gradual and partially irreversible deterioration of the airways. Patients generally suffer from a chronic cough

2016 Prescrire

123. Pulmonary Rehabilitation as a Mechanism to Reduce Hospitalizations for Acute Exacerbations of COPD: A Systematic Review and Meta-Analysis

Pulmonary Rehabilitation as a Mechanism to Reduce Hospitalizations for Acute Exacerbations of COPD: A Systematic Review and Meta-Analysis Acute exacerbation of COPD (AECOPD) has a significant impact on health-care use, including physician visits and hospitalizations. Previous studies and reviews have shown that pulmonary rehabilitation (PR) has many benefits, but the effect on hospitalizations for AECOPD is inconclusive.A literature search was carried out to find studies that might help

Full Text available with Trip Pro

2016 EvidenceUpdates

124. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD

Incident opioid drug use and adverse respiratory outcomes among older adults with COPD We evaluated risk of adverse respiratory outcomes associated with incident opioid use among older adults with chronic obstructive pulmonary diseases (COPD).This was a retrospective population-based cohort study using a validated algorithm applied to health administrative data to identify adults aged 66 years and older with COPD. Inverse probability of treatment weighting using the propensity score was used (...) to estimate hazard ratios comparing adverse respiratory outcomes within 30 days of incident opioid use compared to controls.Incident opioid use was associated with significantly increased emergency room visits for COPD or pneumonia (HR 1.14, 95% CI 1.00-1.29; p=0.04), COPD or pneumonia-related mortality (HR 2.16, 95% CI 1.61-2.88; p<0.0001) and all-cause mortality (HR 1.76, 95% CI 1.57-1.98; p<0.0001), but significantly decreased outpatient exacerbations (HR 0.88, 95% CI 0.83-0.94; p=0.0002). Use of more

Full Text available with Trip Pro

2016 EvidenceUpdates

125. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study

Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study The efficacy and safety of twice-daily aclidinium bromide/formoterol fumarate was compared with that of salmeterol/fluticasone propionate in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD).AFFIRM COPD (Aclidinium and Formoterol Findings in Respiratory Medicine COPD) was a 24-week, double-blind, double-dummy, active-controlled study. Patients were randomised (1:1 (...) ) to aclidinium/formoterol 400/12 µg twice-daily via Genuair/Pressair or salmeterol/fluticasone 50/500 µg twice-daily via Accuhaler. The primary end-point was peak forced expiratory volume in 1 s (FEV1) at week 24. Other end-points included Transition Dyspnoea Index (TDI) focal score at week 24, TDI and St George's Respiratory Questionnaire (SGRQ) responders, COPD Assessment Test and SGRQ scores, assessment of COPD symptoms and exacerbations, use of reliever medication, and device preference. Adverse events

Full Text available with Trip Pro

2016 EvidenceUpdates

126. Bringing about change in COPD care ? White paper

Bringing about change in COPD care ? White paper application/octet-stream

2016 Institute of Health Economics

127. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. (PubMed)

A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. Long-term treatment with supplemental oxygen has unknown efficacy in patients with stable chronic obstructive pulmonary disease (COPD) and resting or exercise-induced moderate desaturation.We originally designed the trial to test whether long-term treatment with supplemental oxygen would result in a longer time to death than no use of supplemental oxygen among patients who had stable COPD with moderate resting (...) desaturation (oxyhemoglobin saturation as measured by pulse oximetry [Spo2], 89 to 93%). After 7 months and the randomization of 34 patients, the trial was redesigned to also include patients who had stable COPD with moderate exercise-induced desaturation (during the 6-minute walk test, Spo2 ≥80% for ≥5 minutes and <90% for ≥10 seconds) and to incorporate the time to the first hospitalization for any cause into the new composite primary outcome. Patients were randomly assigned, in a 1:1 ratio, to receive

Full Text available with Trip Pro

2016 NEJM

128. Lower extremity and carotid artery disease in COPD (PubMed)

Lower extremity and carotid artery disease in COPD In view of their common chronic inflammatory process, we sought to determine the linkage between peripheral artery disease and chronic obstructive pulmonary disease (COPD). 107 COPD patients (mean±sd age 64.6±10.4 years, 52.2% male) and 22 control smokers without previously diagnosed peripheral artery disease underwent standardised angiological examination for lower extremity artery disease (LEAD) and carotid artery disease. LEAD (...) was significantly more prevalent in COPD patients than in controls (80.4% versus 54.5%, p=0.002). Among COPD patients, 57.0%, 12.2%, 10.3% and 0.9% were found to be in Fontaine stages I, IIA, IIB and III, respectively. As with carotid artery disease, its frequency increased from 36.4% in controls to 58.9% in COPD patients (p=0.003). Carotid plaque burden, LEAD Fontaine degrees as well as pulse wave index and ankle-brachial index manifested significant impairment over percentage predicted forced expiratory

Full Text available with Trip Pro

2016 ERJ open research

129. The role of complement activation in COPD exacerbation recovery (PubMed)

The role of complement activation in COPD exacerbation recovery Rise in sputum complement (C3a, C5a) levels during COPD exacerbation is associated with recovery time http://ow.ly/ZaPj303xxPf.

Full Text available with Trip Pro

2016 ERJ open research

130. Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT? (PubMed)

Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT? SUMMIT supports the efficiency and cardiovascular safety of LABA and ICS in COPD patients at cardiovascular risk http://ow.ly/p6Is300ffoc.

Full Text available with Trip Pro

2016 ERJ open research

131. Effect of "add-on" interventions on exercise training in individuals with COPD: a systematic review. (PubMed)

Effect of "add-on" interventions on exercise training in individuals with COPD: a systematic review. The aim of this review was to identify the effectiveness of therapies added on to conventional exercise training to maximise exercise capacity in patients with chronic obstructive pulmonary disease (COPD). Electronic databases were searched, identifying trials comparing exercise training with exercise training plus "add-on" therapy. Outcomes included peak oxygen uptake (V'O2peak), work rate (...) fewer studies, but revealed minimal differences to the primary analysis. The lack of systematic benefits of "add-on" interventions is a probable reflection of methodological limitations, such as "one size fits all" eligibility criteria, that are inherent in many of the included studies of "add-on" therapies. Future clarification regarding the exact value of such therapies may only arise from adequately powered, multicentre clinical trials of tailored interventions for carefully selected COPD patient

Full Text available with Trip Pro

2016 ERJ open research

132. Resilience as a concept for understanding family caregiving of adults with Chronic Obstructive Pulmonary Disease (COPD): an integrative review (PubMed)

Resilience as a concept for understanding family caregiving of adults with Chronic Obstructive Pulmonary Disease (COPD): an integrative review This paper was a report of the synthesis of evidence on examining the origins and definitions of the concept of resilience, investigating its application in chronic illness management and exploring its utility as a means of understanding family caregiving of adults with Chronic Obstructive Pulmonary Disease.Resilience is a concept that is becoming (...) relevant to understanding how individuals and families live with illness, especially long-term conditions. Caregivers of adults with Chronic Obstructive Pulmonary Disease must be able to respond to exacerbations of the condition and may themselves experience cognitive imbalances. Yet, resilience as a way of understanding family caregiving of adults with COPD is little explored.Literature review - integrative review.CINAHL, PubMed, Google Scholar and EBSCO were searched between 1989-2015.The principles

Full Text available with Trip Pro

2016 Nursing open

133. Oxygen-Induced Hypercapnia in COPD: What is the Mechanism?

Oxygen-Induced Hypercapnia in COPD: What is the Mechanism? Oxygen-Induced Hypercapnia in COPD: What is the Mechanism? – Clinical Correlations Search Oxygen-Induced Hypercapnia in COPD: What is the Mechanism? September 28, 2016 5 min read By Jonathan Glatt Peer Reviewed It was my first week on the wards as a third-year medical student, and I found myself huddled with the team in a busy corner of the Bellevue ED, listening to a man cough and wheeze his way through an interview. He was an elderly (...) patient with an extensive smoking history–a lifetime of a destructive habit that had dilated and distorted his lungs beyond repair. He told us, between bouts of breathlessness, of worsening dyspnea and copious sputum production over the past couple of days, riding into his diseased alveoli on the viral coattails of a recent upper respiratory infection. Armed with a presumptive diagnosis of acute chronic obstructive pulmonary disease (COPD) exacerbation, we proceeded to manage his symptoms in full

2016 Clinical Correlations

134. Sleep quality disturbances and cognitive functioning in elderly patients with COPD (PubMed)

Sleep quality disturbances and cognitive functioning in elderly patients with COPD Information about the association between cognitive functions, such as copying function, and sleep disturbances in patients with chronic obstructive pulmonary disease (COPD) is lacking. This cross-sectional observational study aimed to investigate the association between copying function and self-reported sleep quality disturbances and disease severity in an elderly COPD population. Cognitive function (...) performances, assessed using the Mini-Mental State Examination, were compared in 562 ambulatory COPD patients with and without sleep disturbances; assessed using the Established Populations for Epidemiologic Studies of the Elderly questionnaire; and stratified by Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades. Sleep disturbances overall were not correlated with cognitive functioning. A trend was revealed towards worse design copying in patients with sleep disturbances overall. GOLD I

Full Text available with Trip Pro

2016 ERJ open research

135. Prevalence of Osteoporosis and Its Risk Factors in Men with COPD in Qazvin (PubMed)

Prevalence of Osteoporosis and Its Risk Factors in Men with COPD in Qazvin Introduction. Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Proper diagnosis of osteoporosis as a systemic adverse effect of COPD is of significant importance. The present study aimed at evaluating the prevalence of osteoporosis and its risk factors in men suffering from COPD in Qazvin (2014). Methods. This descriptive-analytical study was conducted on 90 patients (...) with COPD using random sampling. Anthropometric data and results from physical examination were collected. Pulmonary function test and bone mineral densitometry were done for all participants as well. Results. The prevalence of osteopenia and osteoporosis in COPD patients was 31.5 and 52.8 percent, respectively. Bone mineral density (BMD) at the femoral neck was associated significantly with body mass index (BMI), increased severity of COPD, and use of oral corticosteroid (P < 0.05). Conclusion

Full Text available with Trip Pro

2016 International journal of chronic diseases

136. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. (PubMed)

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored efficacy trials involving groups of patients who were selected on the basis of restricted entry criteria. There is a need for randomized trials to be conducted in conditions that are closer to usual clinical practice.In a controlled effectiveness trial conducted in 75 general practices, we randomly assigned 2799 (...) patients with COPD to a once-daily inhaled combination of fluticasone furoate at a dose of 100 μg and vilanterol at a dose of 25 μg (the fluticasone furoate-vilanterol group) or to usual care (the usual-care group). The primary outcome was the rate of moderate or severe exacerbations among patients who had had an exacerbation within 1 year before the trial. Secondary outcomes were the rates of primary care contact (contact with a general practitioner, nurse, or other health care professional

Full Text available with Trip Pro

2016 NEJM

137. A validation of the National Early Warning Score to predict outcome in patients with COPD exacerbation (PubMed)

A validation of the National Early Warning Score to predict outcome in patients with COPD exacerbation The National Early Warning Score (NEWS), proposed as a standardised track and trigger system, may perform less well in acute exacerbation of COPD (AECOPD). This study externally validated NEWS and modifications (Chronic Respiratory Early Warning Score (CREWS) and Salford-NEWS) in AECOPD.An observational cohort study (2012-2014, two UK acute medical units (AMUs)), compared AECOPD (2361

2016 EvidenceUpdates

138. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. (PubMed)

Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Bronchodilators are a central component for treating exacerbations of chronic obstructive pulmonary disease (COPD) all over the world. Clinicians often use nebulisers as a mode of delivery, especially in the acute setting, and many patients seem to benefit from them. However, evidence supporting this choice from systematic analysis is sparse, and available data are frequently biased by the inclusion (...) searched the Cochrane Airways Group Trial Register and reference lists of articles up to 1 July 2016.RCTs of both parallel and cross-over designs. We included RCTs during COPD exacerbations, whether measured during hospitalisation or in an outpatient setting. We excluded RCTs involving mechanically ventilated patients due to the different condition of both patients and airways in this setting.Two review authors independently assessed studies for inclusion, extracted data and assessed the risk of bias

Full Text available with Trip Pro

2016 Cochrane

139. Umeclidinium bromide/Vilanterol. Anoro for COPD. No additions to efficacy just to price

Umeclidinium bromide/Vilanterol. Anoro for COPD. No additions to efficacy just to price 2015. DAR No 6: Umeclidinium bromide/Vilanterol. Anoro® for COPD - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 6: Umeclidinium bromide/Vilanterol. Anoro® for COPD DAR No 6: Umeclidinium bromide/Vilanterol. Anoro® for COPD Content tools Share it No additions to efficacy, just to price Umeclidinium/vilanterol is a combination of a muscarinic

2016 Drug and Therapeutics Bulletin of Navarre (Spain)

140. Umeclidinium bromide. Incruse for COPD. Very little efficacy

Umeclidinium bromide. Incruse for COPD. Very little efficacy 2015. DAR No 5: Umeclidinium bromide. Incruse® for COPD - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 5: Umeclidinium bromide. Incruse® for COPD DAR No 5: Umeclidinium bromide. Incruse® for COPD Content tools Share it Very little efficacy Umeclidinium is a long acting muscarinic antagonist (LAMA) authorized for symptom relief in patients with Chronic Obstructive Pulmonary (...) Disease (COPD). They are no comparative data available with tiotropium, or with other LAMA or LABA. It has not shown to reduce the number of exacerbations. Neither does it improve quality of life or reduce the need for rescue treatment in studies lasting more than 12 weeks. There is concern on safety regarding its cardiovascular profile and the possible higher risk of pneumonia. Enviar comentario You can send us a comment or suggestion and we will respond to most frequently asked questions Competing

2016 Drug and Therapeutics Bulletin of Navarre (Spain)